Fig. 1.

MADRS total score change from baseline in patient subgroups. Differences for vilazodone versus placebo in MADRS total score change from baseline were significant in each patient subgroup tested. (a) Catagorized by demographics and baseline symptom severity. (b) Categorized by MDD history. ***P<0.001 versus placebo. ES, effect size (Cohen’s d); LS, least squares; LSMD, least squares mean difference; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; mo, months; n, number of patients with an available MADRS total score at week 8; y, years.